24/7 Market News Snapshot 06 October, 2025 – Immix Biopharma, Inc. Common Stock (NASDAQ:IMMX)

October 6, 2025

DENVER, Colo., 06 October, 2025 (www.247marketnews.com) – (NASDAQ:IMMX) are discussed in this article.
Immix Biopharma, Inc. (IMMX) is experiencing significant upward momentum in the market, with trading commencing at $2.051 and currently priced at $2.245, an increase of approximately 8.98%. Following a previous close at $2.060, the trading volume has reached 677.81K, demonstrating heightened investor interest. Technical analysis suggests potential resistance near $2.30 and support around the $2.00 mark, indicating that traders should closely monitor these critical levels as the stock approaches key psychological benchmarks. The prevailing bullish signals surrounding IMMX make it a focus for further observation regarding potential breakout opportunities.

In parallel, ImmixBio is making strides in the clinical arena, particularly in the treatment of relapsed/refractory AL amyloidosis. The company has confirmed its participation in the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition, scheduled for December 6-9, 2025, where it will showcase an abstract on its innovative CAR-T cell therapy, NXC-201. This condition, marked by the accumulation of misfolded protein amyloids in vital organs, affects an estimated 37,270 individuals in 2025, with annual cases rising at a rate of 12%. The amyloidosis market is projected to grow from $3.6 billion in 2017 to $6 billion by 2025, underscoring the urgent need for effective therapeutic options.

NXC-201, ImmixBio’s lead candidate, is a BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy that has received Orphan Drug Designation from both the FDA and EMA, along with RMAT designation to expedite development. The therapy is currently under investigation in the NEXICART-2 clinical trial, with interim results recently highlighted at ASCO 2025. ImmixBio remains committed to pioneering advancements in this field, aiming to transform the treatment landscape for AL amyloidosis and enhance patient outcomes. Further details regarding their ASH presentation will be forthcoming as the event nears.

Related news for (IMMX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.